ARCHIVES

GPC Biotech’s Satraplatin Fails To Extend Survival In Hormone-Refractory Prostate Cancer.

This article is from The Cancer Letter archive.

Vol. 33 No. 40 | November 2, 2007

Download PDF Visit The Full Archive

Related Articles

NCI Advisors Approve New Grant Programs Worth $100 Million

March 27, 2009

Cancer Program Progress Detailed

March 5, 1976

In Brief: Peter Fischinger Names NCI Deputy Director; ACR Moves Headquarters To Washington Area

November 8, 1985

Continuing Resolution Expires March 27; NIH, NCI Hope For Budget Compromise

March 15, 2013

In Brief: Brinkley Asks Subcommittee to Add $62.5 Million To NCI Budget for Unfunded Grants

May 11, 1979

2006 demonstration project to pay $23 per office visit.

November 4, 2005